WEE1 and pancreatic ductal adenocarcinoma: This study evaluated the combinational effect of a DNA-damaging agent and a WEE1 inhibitor (AZD 1775) in patient-derived organoids (PDOs) generated from pancreatic ductal adenocarcinoma (PDAC) cells.